A Study of LY3437943 in Participants With Impaired and Normal Liver Function

NCT05916560 · Completed

Last updated 2026-05-28

This study tests the effects of the drug LY3437943 on people with and without liver problems to see how the body processes it.

Status Completed The study has finished.

Phase Phase 1 Checks safety and dosing in a small group.

Type Interventional (clinical trial)

Design Non-randomized, open-label (no blinding) basic-science study

Participants 43 people

Who can join Ages 18–85 · all sexes Healthy volunteers accepted.

Timeline Started 2023-07 · est. completion 2025-03

Where 5 sites · United States

What this study is testing ClinicalTrials.gov NCT05916560 ↗

Description as written by the study sponsor.

The main purpose of this study is to measure how much of LY3437943 gets into the bloodstream and how long it takes the body to eliminate it in participants with mild, moderate and severe impaired liver function compared to healthy participants with normal liver function. The safety and tolerability of LY3437943 will also be evaluated. The study may last up to 9 weeks for each participant including the screening period.

Treatments tested

LY3437943 Drug

Administered SC.

Main thing measured	Pharmacokinetics (PK): Area under the concentration versus time curve from time zero to infinity (AUC0-∞) of LY3437943
Sponsor	Eli Lilly and Company
Conditions studied	Healthy, Hepatic Insufficiency
GLP-1 drugs	—

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT05916560 ↗